BOFA $Eli Lilly and Co (LLY.US)$ full SURMOUNT-OSA results A...
BOFA $Eli Lilly and Co(LLY.US$ full SURMOUNT-OSA results ADA supporting regulatory approval In patients with moderate-to-severe OSA and obesity, tirzepatide treatment resolved disease in 43-51.5% of patients
impressive magnitude of response, expect LLY shares to trade with strength on Monda
impressive magnitude of response, expect LLY shares to trade with strength on Monda
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment